51 ASTOR PLACE, 10TH FLOOR, NEW YORK, NY
Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
Reports First Quarter 2026 Results and Meaningful Clinical Progress Advancing Toward Submission for PMA Approval Following Late-Breaking FULCRUM-VT Data
Annual Report to Security Holders
Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
Shareholder Director Nominations
Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System Designed to Deliver Faster, More Efficient Ablation with Improved Usability on Established, Titratable, Endocardial-Approach ULTA Platform
Financial Results, Press Release
Election of Directors at Adagio Medical Holdings Annual Meeting
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
S-8 POS